New drug target could change chronic pain medication
Chronic pain is "the most common cause of long-term disability," according to the National Institutes of Health (NIH).
In fact, a recent analysis from the NIH estimates that more than 25 million people in the United States (or over 11 percent of the country's adult population) live with chronic pain. This means that they have experienced pain every day for the past 3 months.
While in some cases chronic pain may have been initially triggered by an incident such as an injury or an infection, most of the time, the cause of chronic pain is unknown.
Because its causes remain largely unknown, chronic pain cannot yet be cured. However, drugs usually help, and researchers are hard at work trying to come up with more effective treatments.
Now, a new study - published in the journal PLOS Biology - has identified a potential novel therapeutic target for chronic pain, which could help researchers to develop an alternative medication to treat pain in the near future.
The team was led by Dr. Matthew Dalva, of the Department of Neuroscience at Thomas Jefferson University in Philadelphia, PA. He and his team have investigated a process called phosphorylation and its impact on how chronic pain occurs and what sensations it triggers.
Phosphorylation is a term that describes a common biological process whereby a protein changes in response to external stimuli.
Identifying a new pain receptor
Previous research has identified a pain receptor called N-methyl-D-aspartate (NMDA) and the fact that it plays a key role in pathologic pain.
However, this receptor is also important in memory and learning, so drugs that would target this receptor would also affect these functions.
But in the new study, Dr. Dalva and colleagues identified a second receptor that also plays a crucial role in pain. In their study, the scientists examined neurons in particular.
Post a Comment